Compare Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Sht-Term Inflation-Protected Sec Idx ETF vs Viatris Inc — how do they compare? Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 3.6× Viatris Inc's market cap, and Viatris Inc pays a 2.74% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days and Viatris Inc for 57 Days on average.
| VTIP | VTRS | |
|---|---|---|
Market Cap | $73.20B | $20.12B |
Volume | 2,480,668 | 7,543,511 |
52-Week High | $50.46 | $18.27 |
52-Week Low | $48.38 | $9.74 |
Typical Hold Time | 91 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTIP trades at $48.46, up 0.08% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The ETF, focused on short-term inflation-protected securities, shows strong institutional interest, with firms like NewEdge Advisors increasing positions by 45.5% in Q2 2026 (SEC filing, September 2026). Recent news highlights its role in hedging inflation amid rising energy prices and Fed rate hikes.
The outlook for VTIP is supported by its inflation-hedging appeal in a high-rate environment, but risks include interest rate sensitivity and competition from other TIPS ETFs. Wall Street sentiment is cautious yet constructive, given its low-cost structure and short-duration focus, positioning it as a defensive allocation for investors seeking inflation protection without significant rate risk.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
